Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05177055
Other study ID # 66304-2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 23, 2022
Est. completion date December 31, 2027

Study information

Verified date March 2024
Source Haukeland University Hospital
Contact Ane Wilhelmsen-Langeland, PhD
Phone +47 55957000
Email ane.wilhelmsen-langeland@helse-bergen.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sleep disorders commonly co-occur with psychiatric disorders. Sleep disorders are often treated with medication or not at all in psychiatric care, although there exist a plethora of documentation of the effectiveness of sleep interventions. There is also an increase in studies showing effectiveness of sleep-interventions when the sleep disorder co-occurs with psychiatric illness. The recommended treatment for Delayed Sleep-Wake phase disorder is light therapy at gradually advanced timing and/or melatonin administered in order to help phase-advance the circadian rhythm. There is a great gap in the knowledge on how sleep disorders can be treated effectively when they occur comorbid to moderate and severe psychiatric illness. In this project the we therefore seek to investigate the effect of psychological and behavioural, group-based treatment in a randomized controlled trial (RCT) where sleep and psychiatric symptoms are the primary outcome measures.


Description:

The recommended treatment for Delayed Sleep-Wake phase disorder is bright light therapy (LT) at gradually advanced timing and/or melatonin administered in order to phase-advance the circadian rhythm. Recent research has proven that dark therapy, or blocking light in wavelengths <530 nm by the use of for example orange blue-blocking glasses (bb-glasses), has shown the ability to maintain melatonin production comparable to darkness and to have an advancing effect on the circadian rhythm. The investigators therefore also want to test bb-glasses as an additive treatment to LT at gradually advanced timing. The sleep-school at Bjørgvin District Psychiatric Hospital (DPS) is an already established treatment since 2017. The DSWPD-group gets together every other Monday from 1 pm until 3 pm. The group is open, which means that participants start at different dates and meet people in the group that might be at the end of their treatment, this often leads the group to function as a support for each other. Participants are patients at the general psychiatric outpatient clinic at Bjørgvin DPS in Bergen, Norway. Participants have been referred to the sleep-team by their psychologist or doctor. In this RCT the investigators will carry on the same structure for the group for participants that are recruited to the RCT, hence the project has high ecological validity. All participants have an individual consultation before joining the group where the focus is on eligibility to participate in the group-based treatment, sleep-diagnostic evaluation, receive a standardized education on sleep-regulation and sleep hygiene advice and receive a date to start the group-based LT at gradually advanced timing. In a randomized manner, they will be allocated to the sleep-school group and start the treatment on the next possible date or to a 6 week wait-list and receive a date the treatment starts. All eligible participants will be informed that there may be a waitlist and receive a start-date without being informed that thay are on a waitlist group or not a waitlist group. All participants will be treated as usual (TAU) for their psychiatric problems parallel to either sleep-school or waitlist, hence both groups are in active treatment for their symptoms. Participants that start sleep-school as soon as possible, are also allocated to a) ordinary group-based LT at gradually advanced timing for 6 weeks or b) group-based group-based LT at gradually advanced timing for 6 weeks and bb-glasses. All participant will be followed up after 12 months.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 31, 2027
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients referred to the sleep-school at Bjørgvin DPS psychiatric hospital - Patients fulfilling the Diagnostic Manual for Mental Disorders (DSM-V) criteria for DSWPD comorbid to moderate to severe psychiatric illness (confirmed F-diagnosis based on the International Statistical Classification of Diseases and Related Health Problems (ICD-11) diagnostic system that are used in Norway in addition to DSWPD and/or scores of =19 on BDI and/or scores of =16 on BAI at the time of referral to the sleep school) Exclusion Criteria: - Night work - Patients that do not fulfil the DSM-V criteria for DSWPD comorbid to moderate to severe psychiatric illness (confirmed F-diagnosis based on the ICD-10 diagnostic system that are used in Norway in addition to insomnia and/or scores of =19 on BDI and/or scores of =16 on BAI at the time of referral to the sleep school)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Group-based light therapy at gradually advanced timing for DSWPD
Light therapy at gradually advanced timing, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
Group-based light therapy at gradually advanced timing for DSWPD and additive bb-glasses
Light therapy (LT) at gradually advanced timing, bb-glasses 12 hrs after LT, Sleep education, sleep hygiene, cognitive restructuring, relaxation techniques
Other:
6-week wait list for sleep-school
Treatment as usual in a psychiatric outpatient clinic

Locations

Country Name City State
Norway Haukeland University Hospital Bergen Tertnes
Norway Haukeland University Hospital Bergen

Sponsors (2)

Lead Sponsor Collaborator
Haukeland University Hospital University of Bergen

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in degree of experienced pain Measured by a visual analogue scale (VAS Pain) ranging from 0 to 10. The higher the score, the worse the pain. baseline and post intervention after 6 weeks, follow-up after 12 months
Other Changes in self reported emotion regulation ability Measured by Difficulties in Emotion Regulation Scale (DERS) which is a 18-item self-report measure of six facets of emotion regulation. Items are rated on a scale of 1 ("almost never [0-10%]") to 5 ("almost always [91-100%]"). Higher scores suggest greater problems with emotion regulation. baseline and post intervention after 6 weeks, follow-up after 12 months
Other Changes in vigilance Measured by the Conners Continuous Performance (CPT) Test 3rd Edition™ (Conners CPT 3™) baseline and post intervention after 6 weeks, follow-up after 12 months
Other Changes in symptoms of inattention Measured by the Adult attention deficit hyperactivity disorder (ADHD) Self-Rating Scale (ASRS). The scale contains the 18 symptoms of inattention, hyperactivity, and impulsivity defining ADHD according to the DSM-IV-TR and DSM-5. The severity of the symptoms are reported on a 5-point Likert-type scale (0-4 = never, rarely, sometimes, often, to very often), with a total range of 0-72. The higher the score, the more symptoms of inattention. baseline and post intervention after 6 weeks, follow-up after 12 months
Other Changes in symptoms of hypochondria Measured by the The Whiteley Index (WI). The 14-item WI measures assess health anxiety on a likert-scale from 1="not at all" to "5=very much". The higher the score, the more severe health anxiety. baseline and post intervention after 6 weeks, follow-up after 12 months
Other Changes in blood pressure We will measure systolic and diastolic pressure by a digital blood pressure measurement machine. baseline and post intervention after 6 weeks, follow-up after 12 months
Other Changes in Heart rate variability (HRV) 24 -hour HRV. baseline and post intervention after 6 weeks, follow-up after 12 months
Primary Changes (advancement) of sleep timing Measured by sleep diaries, Genactiv actigraphy and saliva samples (intraindividual variation of rise time (IIV), dim light melatonin onset (DLMO), rise /wake up time) baseline, post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in objective sleep onset latency (SOL) Measured by Genactive. The activity recorder is worn on the wrist for 7 consecutive days. The data is downloaded to a computer program that gives the data; a number of minutes of average sleep onset latency. baseline and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in Sleep efficiency (SE) Measured by sleep diary; total sleep time/time in bed x 100= percentage SE baseline, bi-weekly assesment and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in Time in bed (TIB) Measured by sleep diary; time from bed-time to rise time baseline, bi-weekly assesment and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in immediate sleepiness Measured by the Karolinska Sleepiness Scale (KSS). The KSS measure subjective sleepiness at a specific time point (noon). The scale gives a number from 1-9 where 9 indicates "trouble staying awake" and is the worst outcome. baseline, bi-weekly assesment and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in objective total sleep length/time asleep (TST) Measured by Genactive. The activity recorder is worn on the wrist for 7 consecutive days. The data is downloaded to a computer program that gives the data; a number in minutes of average total sleep time. baseline and post intervention after 6 weeks, follow-up after 12 months
Secondary Work status Status of employment/unemployment, percentage disability benefits received baseline and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in Total sleep length/time asleep (TST) Measured by sleep diary; time in minutes from bed-time to estimated sleep onset baseline, bi-weekly assesment and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in Early morning awakening (EMA) Measured by sleep diary; minutes awake before rise time baseline, bi-weekly assesment and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in objective sleep efficiency (SE) Measured by Genactive. The activity recorder is worn on the wrist for 7 consecutive days. The data is downloaded to a computer program that gives the data; a number from 0-100% that gives average sleep efficiency. baseline and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in objective early morning awakening (EMA) Measured by Genactive. The activity recorder is worn on the wrist for 7 consecutive days. The data is downloaded to a computer program that gives the data; a number of average minutes early morning awakening. baseline and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in sleepiness Measured by the Epworth Sleepiness Scale (ESS). The ESS is an 8-item scale where the respondent grades the likelihood of falling asleep or dozing off in different daily situations. The responses are graded on a 4-point likert scale 0=no likelihood to 3=very likely. A score of 11 or higher is considered an indication of excessive daytime sleepiness. baseline, bi-weekly assesment and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in objective wake after sleep onset (WASO) Measured by Genactive. The activity recorder is worn on the wrist for 7 consecutive days. The data is downloaded to a computer program that gives the data; a number of average minutes awake after sleep onset. baseline and post intervention after 8 weeks, follow-up after 12 months
Secondary Changes in beliefs about sleep Measured by Dysfunctional Beliefs About Sleep (DBAS-16). The DBAS-16 measures the degree of dysfunctional beliefs about sleep with 16 items. It has 4 subscales (1) sleep-related worry and helplessness; 2) beliefs about sleep medications; 3) expectations about sleep need; and 4) beliefs about the consequences/effects of insomnia and 1 total scale score. The higher the score, the more dysfunctional beliefs about sleep. baseline and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in objective time in bed (TIB) Measured by Genactive. The activity recorder is worn on the wrist for 7 consecutive days. The data is downloaded to a computer program that gives the data; a number in minutes of average time in bed. baseline and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in Sleep onset latency (SOL) Measured by sleep diary; time in minutes from bed-time to estimated sleep onset baseline, bi-weekly assesment and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in Sleep quality (SQ) Measured by sleep diary; subjective assesment of sleep quality on a scale from 1=very light to 5=very deep baseline, bi-weekly assesment and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in Wake after sleep onset (WASO) Measured by sleep diary; minutes awake before rise time baseline, bi-weekly assesment and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in anxiety symptoms Measured by The Beck Anxiety Inventory (BAI). The BAI measure subjective symptoms of anxiety on a scale ranging from 0-63. The higher the score, the worse the anxiety. baseline and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in depression symptoms Measured by The Beck Depression Inventory-2 (BDI-II). The BDI measure subjective symptoms of depression on a scale ranging from 0-63. The higher the score, the worse depression. baseline and post intervention after 6 weeks, follow-up after 12 months
Secondary Client Satisfaction Measured by the Client Satisfaction Questionnaire (CSQ8). The CSQ-8 is an 8-item questionnaire that measures patient satisfaction with health services, where the items are rated from 1 (very low satisfaction) to 4 (very high satisfaction). The total score ranges from 8 to 32, with higher scores indicating higher degrees of satisfaction. post intervention after 6 weeks
Secondary Changes in Daytime function (DF) Measured by sleep diary; subjective assesment of daytime function on a scale from 1=very good to 5=very poor baseline, bi-weekly assesment and post intervention after 6 weeks, follow-up after 12 months
Secondary Suicide attempts and admittances in psychiatric wards Whether or not suicide has been attempted, if applicable number og attempts and whether or nor the patient has been admitted to a psychitaric ward (voluntary/forced) baseline and post intervention after 6 weeks, follow-up after 12 months
Secondary Changes in anxiety and depression Measured by the Hospital anxiety and depression scale (HADS), Beck Depression Inventory (BDI-II) and Beck Anxiety Inventory (BAI) baseline, bi-weekly assesment and post intervention after 6 weeks, follow-up after 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Recruiting NCT04786314 - The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome N/A
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Recruiting NCT03326765 - Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC) N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT03903263 - Sleep Disturbances in Dermatology Patients
Not yet recruiting NCT06012513 - Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis
Not yet recruiting NCT05950932 - Effects of Melissa Extract on Sleep Characteristics Phase 4
Completed NCT01463839 - Sleep Disorder and Oral Habits in Children N/A
Completed NCT00940589 - Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor Phase 2
Recruiting NCT06093633 - A Prospective Study to Evaluate the WP in Comparison to PSG in Patients Suspected of Sleep Disorders
Completed NCT06108115 - Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder N/A
Completed NCT05511818 - Radicle Rest: A Study of Cannabinoids on Sleep and Health Outcomes N/A
Active, not recruiting NCT04291014 - Light Therapy for PD - Dose Selection N/A
Completed NCT04560595 - Remote Guided Caffeine Reduction N/A
Completed NCT06008470 - Investigation of Respiratory Muscle Strength, Exercise Capacity, Physical Activity and Sleep Quality Level in Individuals With Covid-19 Infection
Recruiting NCT06129942 - Light Therapy in Parkinson's Disease N/A
Recruiting NCT04318067 - Melatonin in ADHD and Sleep Problems Phase 4
Completed NCT03857802 - Efficiency of a Nursing Intervention in Sleep Hygiene N/A
Completed NCT03532269 - Validation of the Sleep Assessment Algorithm in the Medical Application Nightly N/A